Precautions when using Mirikizumab

Mirikizumab (Mirikizumab)-Omvoh is a new treatment drug that has shown good efficacy in clinical studies in recent years, but is also accompanied by some potential safety issues. When using Omvoh for treatment, special attention needs to be paid to the following key warnings and precautions to ensure patient safety and treatment effectiveness.

1. Allergic reaction is a problem that needs to be paid attention to when usingOmvoh. It has been reported that some patients have experienced severe allergic reactions after administration, especially during intravenous infusion. Infusion-related allergic reactions, such as skin and mucous membrane erythema and itching, may occur. These reactions may affect the patient's overall health, so if a severe allergic reaction is detected, it is important to stop the use of Omvoh immediately and conduct appropriate medical intervention to prevent further health risks.

2. The risk of infection is also an important factor to consider when usingOmvoh. Studies have shown that Omvoh may increase the risk of infection, so for those patients who already have an active infection, Omvoh treatment should not be started until the infection is effectively controlled. In addition, doctors should carefully evaluate the risks versus benefits before prescribing for patients with a history of chronic or recurring infections. If patients develop symptoms associated with an acute or chronic infection, they should be instructed to seek medical help as soon as possible and to avoid using Omvoh until the infection resolves.

3. Regarding the management of tuberculosis, doctors need to conduct a detailed assessment of the patient's tuberculosis infection before starting Omvoh treatment. This drug is absolutely contraindicated in patients with active tuberculosis infection. Before starting treatment, patients with latent tuberculosis infection should receive appropriate anti-tuberculosis treatment. Antituberculous treatment is recommended for patients with a past history of tuberculosis, especially those who have not been confirmed to have completed an adequate course of treatment. During and after treatment with Omvoh, patients should be regularly monitored for symptoms related to active tuberculosis to ensure patient safety.

4. Liver toxicity is also an important issue that cannot be ignored. In a clinical trial, there was a report of drug-induced liver injury. After the patient received a longer-than-recommended induction regimen, his alanine aminotransferase (ALT) level increased significantly, reaching 18 times the upper limit of normal, and aspartate aminotransferase (AST) was also higher than the normal range. Therefore, patients' liver enzyme and bilirubin levels need to be evaluated regularly during treatment and monitored according to routine patient management. For patients with evidence of cirrhosis, other treatment options should be considered and the cause of elevated liver enzymes promptly investigated to determine whether potential drug-induced liver injury exists. If it is suspected that the patient may have liver damage, treatment should be interrupted promptly, and the patient should be advised to seek medical treatment immediately if symptoms of abnormal liver function occur.

5. Regarding immunization, doctors should remind patients to avoid the use of live vaccines during treatment with Omvoh. Because Omvoh interacts with the immune system, use of live vaccines may increase the risk of infection. Therefore, before initiating treatment, patients should complete all age-appropriate vaccinations according to current immunization guidelines. There are currently no data on the response of Omvoh-treated patients to live or non-live vaccines, which also increases the risk of adverse reactions that may occur after vaccination.

To sum up,The use of Omvoh needs to be strictly monitored by doctors, especially in aspects such as allergic reactions, infections, tuberculosis, hepatotoxicity and immunization. Through reasonable management of these risk factors, patients can be provided with safer and more effective treatment options to achieve optimal treatment results.

References:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472cbe04-263e-433d-9a0f-58c1b50b715a